Unlike typical drugs with inelastic demand, the market for GLP-1s is price-elastic. Eli Lilly's CEO confirms that lowering prices directly expands the user base, creating a rare instance where capitalist incentives align with broader consumer access in the pharmaceutical industry.

The GLP-1 market is projected to face intense competition from both generics (like statins) and high-rebate branded drugs (like ED medications). This dual pressure will squeeze profit margins, drive net prices down significantly, and ultimately compel broad payer coverage due to the drugs' strong clinical return on investment.

The GLP-1 drug revolution is moving beyond weekly injections for wealthy markets. Upcoming pill-form versions will eliminate the need for refrigerated supply chains, opening up distribution in developing countries. Combined with expiring patents, this focus on form factor and cost will enable mass global adoption.

The surge in use of compounded GLP-1s, costing about half the price of branded versions, demonstrates huge untapped demand. Patients are willing to accept manufacturing and safety risks for affordability, proving price is a major barrier to adoption.

In explosive markets like GLP-1 drugs, significant price drops and margin compression (e.g., from 80% to 60%) don't necessarily harm profits. The sheer volume of new customers can completely offset lower per-unit profitability, leading to far greater overall earnings.

The key catalyst for GLP-1 weight-loss drugs becoming mainstream wasn't just effectiveness, but a drastic price drop. Moving from over $1,000/month to as low as $25/month with insurance transformed the drug from a luxury good into an accessible, subscription-like product, paving the way for mass adoption.

The transition to oral GLP-1 therapies is a significant market expander, not just a convenience upgrade. Nearly 80% of patients starting oral medications are new to the drug category, indicating a substantial increase in the addressable patient pool rather than simple conversion of existing users.

India produces 60% of the world's drugs by volume but captures only 2-5% of the revenue. This disparity exists because it dominates the post-patent generic market, where prices can fall by over 95%, while innovator companies capture the high-margin monopoly period.

Despite the arrival of low-cost generic semaglutide, superior drugs like Tirzepatide, which offers better efficacy and tolerability, can command premium prices. This creates a durable, high-value market segment that coexists with, rather than being eroded by, cheaper alternatives.